Entecavir (BioDeep_00000033234)
human metabolite blood metabolite Chemicals and Drugs
代谢物信息卡片
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-6,9-dihydro-3H-purin-6-one
化学式: C12H15N5O3 (277.117484)
中文名称: 恩替卡韦
谱图信息:
最多检出来源 Homo sapiens(blood) 32.48%
分子结构信息
SMILES: C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N
InChI: InChI=1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1
描述信息
Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS). Entecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the manufacturer claims that it is more efficacious than previous agents used to treat hepatitis B (lamivudine and adefovir). It was approved by the U.S. Food and Drug Administration (FDA) in March 2005.
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AF - Nucleoside and nucleotide reverse transcriptase inhibitors
C471 - Enzyme Inhibitor > C1589 - Reverse Transcriptase Inhibitor > C97452 - Nucleoside Reverse Transcriptase Inhibitor
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents
C254 - Anti-Infective Agent > C281 - Antiviral Agent
同义名列表
数据库引用编号
11 个数据库交叉引用编号
- ChEBI: CHEBI:473990
- ChEBI: CHEBI:59902
- PubChem: 135398508
- PubChem: 153941
- HMDB: HMDB0014585
- DrugBank: DB00442
- ChEMBL: CHEMBL713
- Wikipedia: Entecavir
- chemspider: 135679
- CAS: 1333204-94-6
- CAS: 142217-69-4
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Dabing Ping, Jingshu Qi, Meng Li, Xin Sun, Yuan Peng, Chenghai Liu. Fuzheng Huayu recipe alleviates liver fibrosis via inhibiting NLRP3 inflammasome activation in macrophages.
Journal of ethnopharmacology.
2024 Jan; 318(Pt B):117001. doi:
10.1016/j.jep.2023.117001. [PMID: 37544346] - D Y Cheng, P Guo, F X Sun, X J Wang, W Li, Q Chen, G Q Zhou, R B Wang, H C Xing. [Clinical efficacy of entecavir combined with Biejiajian pills and its influence on TCM syndrome scores during the treatment of chronic hepatitis B with hepatic fibrosis and blood stasis syndrome].
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.
2023 Jun; 31(6):608-613. doi:
10.3760/cma.j.cn501113-20230217-00065. [PMID: 37400385] - Chen Wenlin, Liang Fang, Zhang Yuncheng, L V Jinzhen, Yang Daguo. Effects of Zhenggan Huayu decoction combined with entecavir on gut microbiota in patients with chronic hepatitis B fibrosis.
Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.
2023 06; 43(3):559-567. doi:
10.19852/j.cnki.jtcm.20230208.002. [PMID: 37147758] - Yufeng Xing, Weichao Zhong, Deti Peng, Zhiyi Han, Hua Zeng, Yanqing Wang, Lian Feng, Jinzhen Huang, Linyi Xu, Mingtai Chen, Daqiao Zhou, Kaiping Jiang, Xin Deng, Hua Zhou, Guangdong Tong. Chinese herbal formula ruangan granule enhances the efficacy of entecavir to reverse advanced liver fibrosis/early cirrhosis in patients with chronic HBV infection: A multicenter, randomized clinical trial.
Pharmacological research.
2023 Apr; 190(?):106737. doi:
10.1016/j.phrs.2023.106737. [PMID: 36940891] - H Chen, H X Yuan, X H Li. [Meta-analysis of the clinical efficacy of live bifidobacterium bacteria preparation combined with entecavir in the treatment of hepatitis B virus-related cirrhosis].
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.
2023 Mar; 31(3):258-264. doi:
10.3760/cma.j.cn501113-20230309-00097. [PMID: 37137851] - Won-Mook Choi, Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, W Ray Kim, Leland J Yee, Craig Brooks-Rooney, Tristan Curteis, Harriet Cant, Chien-Hung Chen, Chi-Yi Chen, Yi-Hsiang Huang, Young-Joo Jin, Dae Won Jun, Jin-Wook Kim, Neung Hwa Park, Cheng-Yuan Peng, Hyun Phil Shin, Jung Woo Shin, Yao-Hsu Yang, Young-Suk Lim. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis.
Journal of hepatology.
2023 03; 78(3):534-542. doi:
10.1016/j.jhep.2022.12.007. [PMID: 36572349] - Aijie Zhang, Fanlong Yang, Yang Yuan, Cai Li, Xiaokui Huo, Jing Liu, Shenzhi Zhou, Wei Li, Na Zhang, Jianfeng Liu, Shiqi Dong, Huirong Fan, Ying Peng, Jiang Zheng. OAT3 Participates in Drug-Drug Interaction between Bentysrepinine and Entecavir through Interactions with M8-A Metabolite of Bentysrepinine-In Rats and Humans In Vitro.
Molecules (Basel, Switzerland).
2023 Feb; 28(4):. doi:
10.3390/molecules28041995. [PMID: 36838982] - Dong Ji, Yan Chen, Jingfeng Bi, Qinghua Shang, Huabao Liu, Jia-Bo Wang, Lin Tan, Jing Wang, Yongping Chen, Qin Li, Qinghua Long, Laicheng Song, Li Jiang, Guangming Xiao, Zujiang Yu, Liang Chen, Xiaodong Wang, Da Chen, Zhiqin Li, Zheng Dong, Yongping Yang. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.
Journal of hepatology.
2022 12; 77(6):1515-1524. doi:
10.1016/j.jhep.2022.07.018. [PMID: 35985545] - Zhi-Min Zhao, Chuan-Wu Zhu, Jia-Quan Huang, Xiao-Dong Li, Yu-Xi Zhang, Jian Liang, Wei Zhang, Yong Zhang, Xian-Gao Jiang, Ya-Li Zong, Ke-Jun Zhang, Ke-Wei Sun, Biao Zhang, Yun-Hai Lv, Hui-Chun Xing, Qing Xie, Ping Liu, Cheng-Hai Liu. Efficacy and safety of Fuzheng Huayu tablet on persistent advanced liver fibrosis following 2 years entecavir treatment: A single arm clinical objective performance criteria trial.
Journal of ethnopharmacology.
2022 Nov; 298(?):115599. doi:
10.1016/j.jep.2022.115599. [PMID: 35932973] - Qiankun Hu, Xun Qi, Yiqi Yu, Yueqiu Gao, Xinxin Zhang, Qianqian Wang, Xueyun Zhang, Yunhui Zhuo, Jing Li, Jiming Zhang, Liang Chen, Yuxian Huang. The efficacy and safety of adding on or switching to peginterferon α-2b in HBeAg-positive chronic hepatitis B patients with long-term entecavir treatment: a multicentre randomised controlled trial.
Alimentary pharmacology & therapeutics.
2022 11; 56(9):1394-1407. doi:
10.1111/apt.17222. [PMID: 36128636] - Qi Zhang, Jinlin Liang, Junhua Yin, Yiyue Jiang, Ning Yu, Xingmei Liao, Siru Zhao, Leyuan Wu, Rong Fan. Real-life impact of tenofovir disoproxil fumarate and entecavir therapy on lipid profile, glucose, and uric acid in chronic hepatitis B patients.
Journal of medical virology.
2022 11; 94(11):5465-5474. doi:
10.1002/jmv.27977. [PMID: 35794065] - Dan-Ying Cheng, Zhi-Min Zhao, Gang Wan, Huan-Wei Zheng, Jia-Quan Huang, Cheng-Hai Liu, Hui-Chun Xing. Impact of Fuzheng Huayu tablet on antiviral effect of entecavir in patients with hepatitis B cirrhosis.
Hepatobiliary & pancreatic diseases international : HBPD INT.
2022 Oct; 21(5):479-484. doi:
10.1016/j.hbpd.2022.03.007. [PMID: 35346577] - Mohamed Hamdi, Enas Elmowafy, Hend Mohamed Abdel-Bar, Akram M ElKashlan, Khuloud T Al-Jamal, Gehanne A S Awad. Hyaluronic acid-entecavir conjugates-core/lipid-shell nanohybrids for efficient macrophage uptake and hepatotropic prospects.
International journal of biological macromolecules.
2022 Sep; 217(?):731-747. doi:
10.1016/j.ijbiomac.2022.07.067. [PMID: 35841964] - Mingyuan Zhang, Haikun Zhang, Xiaoming Cheng, Xiaomei Wang, Hongqin Xu, Xiuzhu Gao, Ruihong Wu, Dake Zhang, Yuchen Xia, Junqi Niu. Liver biopsy of chronic hepatitis B patients indicates HBV integration profile may complicate the endpoint and effect of entecavir treatment.
Antiviral research.
2022 08; 204(?):105363. doi:
10.1016/j.antiviral.2022.105363. [PMID: 35709897] - Juhan Lee, Jae Geun Lee, Shin Hwang, Kwang-Woong Lee, Jong Man Kim, Je Ho Ryu, Bong-Wan Kim, Dong Lak Choi, Young Kyoung You, Dong-Sik Kim, Yang Won Nah, Koo Jeong Kang, Jai Young Cho, Hee Chul Yu, Geun Hong, Dongho Choi, Ju Ik Moon, Myoung Soo Kim. Renal safety of tenofovir disoproxil fumarate and entecavir in liver transplant patients: a nationwide Korean registry study.
Hepatology international.
2022 Jun; 16(3):537-544. doi:
10.1007/s12072-022-10320-z. [PMID: 35467324] - Po-Ke Hsu, Pei-Yuan Su, Chia-Lin Wu. Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B.
BMC gastroenterology.
2022 May; 22(1):228. doi:
10.1186/s12876-022-02317-7. [PMID: 35538425] - Avery S Ward, Chia-Heng Hsiung, Daniel G Kesterson, Vasudeva G Kamath, Edward E McKee. Entecavir competitively inhibits deoxyguanosine and deoxyadenosine phosphorylation in isolated mitochondria and the perfused rat heart.
The Journal of biological chemistry.
2022 05; 298(5):101876. doi:
10.1016/j.jbc.2022.101876. [PMID: 35358513] - Xin-Fu Xie, Bing-Ying Xie, Wen-Hao Zhang, Ji-Hua Hou, Ding-Lin Liu, Li Zhang, Li-Xia Xu, Zhi-Lian Li, Rui-Zhao Li, Zhi-Ming Ye. The efficacy and safety of tacrolimus and entecavir combination therapy in the treatment of hepatitis B virus-associated glomerulonephritis: a multi-center, placebo controlled, and single-blind randomized trial.
Annals of palliative medicine.
2022 May; 11(5):1762-1773. doi:
10.21037/apm-22-328. [PMID: 35672893] - Chan-Young Jung, Hyung Woo Kim, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim. Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B.
Liver international : official journal of the International Association for the Study of the Liver.
2022 05; 42(5):1017-1026. doi:
10.1111/liv.15208. [PMID: 35220649] - Young Eun Chon, Soo Young Park, Seung Up Kim, Han Pyo Hong, Jae Seung Lee, Hye Won Lee, Mi Na Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim. Long-term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study.
Journal of viral hepatitis.
2022 04; 29(4):289-296. doi:
10.1111/jvh.13656. [PMID: 35152517] - Man-Fung Yuen, Danny Ka-Ho Wong, Thomas Schluep, Ching-Lung Lai, Carlo Ferrari, Stephen Locarnini, Regina Cheuk-Lam Lo, Robert G Gish, James Hamilton, Christine I Wooddell, Lung Yi Mak, Bruce D Given. Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment.
Gut.
2022 04; 71(4):789-797. doi:
10.1136/gutjnl-2020-323445. [PMID: 33712437] - Chan-Young Jung, Hyung Woo Kim, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim. Tenofovir is Associated With Higher Risk of Kidney Function Decline Than Entecavir in Patients With Chronic Hepatitis B.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
2022 04; 20(4):956-958.e2. doi:
10.1016/j.cgh.2021.05.032. [PMID: 34029751] - Zili Hu, Huilan Zeng, Jingyu Hou, Juncheng Wang, Li Xu, Yaojun Zhang, Minshan Chen, Zhongguo Zhou. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation.
Viruses.
2022 03; 14(4):. doi:
10.3390/v14040656. [PMID: 35458386] - Q P Wen, H Qian, S Ba, M J Lu, L D J Silang, L Shi. [Exploring the effects of entecavir treatment on the degree of liver fibrosis in patients with non-alcoholic fatty liver combined with chronic hepatitis B in Tibet region].
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.
2022 Mar; 30(3):304-308. doi:
10.3760/cma.j.cn501113-20200628-00347. [PMID: 35462487] - J He, Y Q Yao, R X Xia, T J Qiu, L Long, Y Wang, Y Jiang. [Observation of PD-1+CXCR5+CD4+T lymphocyte and sPD-1 levels in HBeAg positive chronic hepatitis B virus carriers treated with entecavir].
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.
2022 Mar; 30(3):316-322. doi:
10.3760/cma.j.cn501113-20191223-00476. [PMID: 35462489] - Guanghua Rong, Yongping Chen, Zujiang Yu, Qin Li, Jingfeng Bi, Lin Tan, Dedong Xiang, Qinghua Shang, Chunliang Lei, Liang Chen, Xiaoyu Hu, Jing Wang, Huabao Liu, Wei Lu, Yan Chen, Zheng Dong, Wenlin Bai, Eric M Yoshida, Nahum Mendez-Sanchez, Ke-Qin Hu, Xingshun Qi, Yongping Yang. Synergistic Effect of Biejia-Ruangan on Fibrosis Regression in Patients With Chronic Hepatitis B Treated With Entecavir: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
The Journal of infectious diseases.
2022 03; 225(6):1091-1099. doi:
10.1093/infdis/jiaa266. [PMID: 32437567] - Chih-Lang Lin, Yi-Lan Lin, Kung-Hao Liang, Li-Wei Chen, Cheng-Hung Chien, Ching-Chih Hu, Ting-Shuo Huang, Yu-Chiau Shyu, Chau-Ting Yeh, Rong-Nan Chien. Prognosis Comparison Between Chronic Hepatitis B Patients Receiving a Finite Course of Tenofovir and Entecavir Treatment: A Nationwide Cohort Study in Taiwan.
Clinical therapeutics.
2022 03; 44(3):403-417.e6. doi:
10.1016/j.clinthera.2022.01.010. [PMID: 35469645] - Wenting Peng, Huimin Gu, Chuan Jiang, Jinqing Liu, Jian Zhang, Lei Fu. Comparison of tenofovir alafenamide and entecavir for hepatitis B virus-related acute-on-chronic liver failure.
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences.
2022 Feb; 47(2):194-201. doi:
10.11817/j.issn.1672-7347.2022.210578. [PMID: 35545409] - Lung-Yi Mak, Joseph Hoang, Dae Won Jun, Chien-Hung Chen, Cheng-Yuan Peng, Ming-Lun Yeh, Sung Eun Kim, Daniel Q Huang, Jae Yoon Jeong, Eileen Yoon, Hyunwoo Oh, Pei-Chien Tsai, Chung-Feng Huang, Sang Bong Ahn, Huy Trinh, Qing Xie, Grace L H Wong, Masaru Enomoto, Jae-Jun Shim, Dong-Hyun Lee, Li Liu, Ritsuzo Kozuka, Yong Kyun Cho, Soung Won Jeong, Hyoung Su Kim, Lindsey Trinh, Allen Dao, Rui Huang, Rex Wan-Hin Hui, Vivien Tsui, Sabrina Quek, Htet Htet Toe Wai Khine, Eiichi Ogawa, Chia Yen Dai, Jee Fu Huang, Ramsey Cheung, Chao Wu, Wan-Long Chuang, Seng Gee Lim, Ming-Lung Yu, Man-Fung Yuen, Mindie H Nguyen. Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study.
Hepatology international.
2022 Feb; 16(1):48-58. doi:
10.1007/s12072-021-10271-x. [PMID: 34822056] - Ritsuzo Kozuka, Masaru Enomoto, Minh Phuong Dong, Hoang Hai, Le Thi Thanh Thuy, Naoshi Odagiri, Kanako Yoshida, Kohei Kotani, Hiroyuki Motoyama, Etsushi Kawamura, Atsushi Hagihara, Hideki Fujii, Sawako Uchida-Kobayashi, Akihiro Tamori, Norifumi Kawada. Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment.
Scientific reports.
2022 01; 12(1):105. doi:
10.1038/s41598-021-03706-w. [PMID: 34996935] - Yoshihito Uchida, Masamitsu Nakao, Shunsuke Yamada, Shohei Tsuji, Hayato Uemura, Jun-Ichi Kouyama, Kayoko Naiki, Kayoko Sugawara, Nobuaki Nakayama, Yukinori Imai, Tomoaki Tomiya, Satoshi Mochida. Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.
PloS one.
2022; 17(2):e0262764. doi:
10.1371/journal.pone.0262764. [PMID: 35180213] - Tetsuya Hosaka, Fumitaka Suzuki, Mariko Kobayashi, Shunichiro Fujiyama, Yusuke Kawamura, Hitomi Sezaki, Norio Akuta, Masahiro Kobayashi, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada. Ultrasensitive Assay for Hepatitis B Core-Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir.
Hepatology communications.
2022 01; 6(1):36-49. doi:
10.1002/hep4.1819. [PMID: 34532993] - Fumitaka Suzuki, Yoshiyuki Suzuki, Yoshiyasu Karino, Yasuhito Tanaka, Masayuki Kurosaki, Hiroshi Yatsuhashi, Tomofumi Atarashi, Masanori Atsukawa, Tsunamasa Watanabe, Masaru Enomoto, Masatoshi Kudo, Naoto Maeda, Hiroshi Kohno, Kouji Joko, Kojiro Michitaka, Koichiro Miki, Kazuhiro Takahashi, Tatsuya Ide, Shigetoshi Fujiyama, Tomoko Kohno, Hiroshi Itoh, Sakiyo Tsukamoto, Yuko Suzuki, Yoshiaki Kawano, Wataru Sugiura, Hiromitsu Kumada. Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study.
BMC gastroenterology.
2021 Dec; 21(1):489. doi:
10.1186/s12876-021-02008-9. [PMID: 34930140] - Yao-Chun Hsu, Ming-Lun Yeh, Grace Lai-Hung Wong, Chien-Hung Chen, Cheng-Yuan Peng, Maria Buti, Masaru Enomoto, Qing Xie, Huy Trinh, Carmen Preda, Li Liu, Ka-Shing Cheung, Yee Hui Yeo, Joseph Hoang, Chung-Feng Huang, Mar Riveiro-Barciela, Ritsuzo Kozuka, Doina Istratescu, Pei-Chien Tsai, Elena Vargas Accarino, Dong-Hyun Lee, Jia-Ling Wu, Jee Fu Huang, Chia-Yen Dai, Ramsey Cheung, Wan-Long Chuang, Man-Fung Yuen, Vincent Wai-Sun Wong, Ming-Lung Yu, Mindie H Nguyen. Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B.
The Journal of infectious diseases.
2021 12; 224(11):1890-1899. doi:
10.1093/infdis/jiab241. [PMID: 33999179] - Yongbin Wu, Jian Wen, Guifang Tang, Jing Zhang, Jie Xin. On-treatment HBV RNA dynamic predicts entecavir-induced HBeAg seroconversion in children with chronic hepatitis B.
The Journal of infection.
2021 11; 83(5):594-600. doi:
10.1016/j.jinf.2021.08.044. [PMID: 34474058] - Meng Hsuan Kuo, Chih-Wei Tseng, Ming-Chi Lu, Chien-Hsueh Tung, Kuo-Chih Tseng, Kuang-Yung Huang, Chi-Hui Lee, Ning-Sheng Lai. Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment.
Digestive diseases and sciences.
2021 11; 66(11):4026-4034. doi:
10.1007/s10620-020-06725-1. [PMID: 33387124] - Xiang-An Zhao, Jian Wang, Jiacheng Liu, Guangmei Chen, Xiaomin Yan, Bei Jia, Yue Yang, Yong Liu, Da Gu, Zhaoping Zhang, Xiaoxing Xiang, Rui Huang, Chao Wu. Baseline serum hepatitis B core antibody level predicts HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B after antiviral treatment.
Antiviral research.
2021 09; 193(?):105146. doi:
10.1016/j.antiviral.2021.105146. [PMID: 34314774] - Feng Lu, Jia-Bao Geng, Jia-Wei Zhang, Yu Dong. Effect of entecavir plus Ganshuang granule on fibrosis and cirrhosis in patients with chronic hepatitis B.
Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.
2021 08; 41(4):624-629. doi:
10.19852/j.cnki.jtcm.2021.03.015. [PMID: 34392656] - Dong Ji, Yan Chen, Qinghua Shang, Huabao Liu, Lin Tan, Jing Wang, Yongping Chen, Qin Li, Qinghua Long, Laicheng Song, Li Jiang, Guangming Xiao, Zujiang Yu, Liang Chen, Xiaoyu Hu, Xiaodong Wang, Da Chen, Zhiqin Li, Zheng Dong, Guofeng Chen, Yongping Yang. Unreliable Estimation of Fibrosis Regression During Treatment by Liver Stiffness Measurement in Patients With Chronic Hepatitis B.
The American journal of gastroenterology.
2021 08; 116(8):1676-1685. doi:
10.14309/ajg.0000000000001239. [PMID: 33840727] - Pao-Yuan Huang, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu, Tsung-Hui Hu, Chien-Hung Chen. The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients.
Journal of viral hepatitis.
2021 08; 28(8):1141-1149. doi:
10.1111/jvh.13528. [PMID: 33932245] - Zheng-Xin Li, Zhi-Min Zhao, Ping Liu, Qing-Shan Zheng, Cheng-Hai Liu. Treatment of HBV Cirrhosis with Fuzheng Huayu Tablet () and Entecavir: Design of a Randomized, Double-Blind, Parallel and Multicenter Clinical Trial.
Chinese journal of integrative medicine.
2021 Jul; 27(7):509-513. doi:
10.1007/s11655-020-3257-6. [PMID: 32572776] - Xi Zhang, Xiaocui An, Lei Shi, Xueliang Yang, Yunru Chen, Xiaojing Liu, Jianzhou Li, Feng Ye, Shumei Lin. Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years.
Scientific reports.
2021 06; 11(1):13389. doi:
10.1038/s41598-021-92757-0. [PMID: 34183689] - Juan Li, Chunhua Hu, Yi Chen, Rou Zhang, Shan Fu, Mimi Zhou, Zhijie Gao, Mengjun Fu, Taotao Yan, Yuan Yang, Jianzhou Li, Jinfeng Liu, Tianyan Chen, Yingren Zhao, Yingli He. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
BMC infectious diseases.
2021 Jun; 21(1):567. doi:
10.1186/s12879-021-06237-x. [PMID: 34126939] - Mindie H Nguyen, Masanori Atsukawa, Toru Ishikawa, Satoshi Yasuda, Keisuke Yokohama, Huy N Trinh, Taeang Arai, Shinya Fukunishi, Eiichi Ogawa, Yao-Chun Hsu, Mayumi Maeda, Hansen Dang, Cheng-Hao Tseng, Hirokazu Takahashi, Dae Won Jun, Tsunamasa Watanabe, Makoto Chuma, Akito Nozaki, Norifumi Kawada, Ramsey Cheung, Masaru Enomoto, Koichi Takaguchi, Hidenori Toyoda. Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir.
The American journal of gastroenterology.
2021 06; 116(6):1264-1273. doi:
10.14309/ajg.0000000000001157. [PMID: 34074829] - Lung-Yi Mak, Gavin Cloherty, Danny Ka-Ho Wong, Jeffrey Gersch, Wai-Kay Seto, James Fung, Man-Fung Yuen. HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy.
Hepatology (Baltimore, Md.).
2021 06; 73(6):2167-2179. doi:
10.1002/hep.31616. [PMID: 33159329] - Si-Qi Wang, Yue Shen, Jing Li, Yun Liu, Li-Sha Cheng, Sheng-Di Wu, Wei-Min She, Wei Jiang. Entecavir-induced interferon-λ1 suppresses type 2 innate lymphoid cells in patients with hepatitis B virus-related liver cirrhosis.
Journal of viral hepatitis.
2021 05; 28(5):795-808. doi:
10.1111/jvh.13476. [PMID: 33482039] - Shi Liu, Yaobo Wu, Rui Deng, Sheng Shen, Rong Fan, Jie Peng, Wanying Li, Xieer Liang, Jinlin Hou, Jian Sun, Bin Zhou. Methodology-dependent performance of serum HBV RNA in predicting treatment outcomes in chronic hepatitis B patients.
Antiviral research.
2021 05; 189(?):105037. doi:
10.1016/j.antiviral.2021.105037. [PMID: 33711337] - Xiujuan Chang, Jing Wang, Yan Chen, Qinghua Long, Laicheng Song, Qin Li, Huabao Liu, Qinghua Shang, Zujiang Yu, Li Jiang, Guangming Xiao, Li Li, Liang Chen, Xiaodong Wang, Zhiqin Li, Da Chen, Zheng Dong, Linjing An, Lin Tan, Yongping Chen, Yongping Yang. A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection.
EBioMedicine.
2021 May; 67(?):103389. doi:
10.1016/j.ebiom.2021.103389. [PMID: 34004423] - Rui Huang, Jiacheng Liu, Jian Wang, Chao Wu. Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis.
Alimentary pharmacology & therapeutics.
2021 05; 53(9):1040-1041. doi:
10.1111/apt.16273. [PMID: 33831236] - Kyle E Korolowicz, Manasa Suresh, Bin Li, Xu Huang, Changsuek Yon, Xuebing Leng, Bhaskar V Kallakury, Robin D Tucker, Stephan Menne. Treatment with the Immunomodulator AIC649 in Combination with Entecavir Produces Antiviral Efficacy in the Woodchuck Model of Chronic Hepatitis B.
Viruses.
2021 04; 13(4):. doi:
10.3390/v13040648. [PMID: 33918831] - Wai-Kay Seto, Kevin Sh Liu, Lung-Yi Mak, Gavin Cloherty, Danny Ka-Ho Wong, Jeffrey Gersch, Yuk-Fai Lam, Ka-Shing Cheung, Ning Chow, Kwan-Lung Ko, Wai-Pan To, James Fung, Man-Fung Yuen. Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation.
Gut.
2021 04; 70(4):775-783. doi:
10.1136/gutjnl-2020-321116. [PMID: 32759300] - H B Ning, H M Jin, K Li, Z Peng, W Li, J Shang. [Analysis of bone mineral density and its influencing factors in 211 patients with chronic hepatitis B treated with long-term entecavir monotherapy].
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.
2021 Mar; 29(3):234-239. doi:
10.3760/cma.j.cn501113-20191128-00436. [PMID: 33902190] - Ming-Chao Tsai, Kuo-Chin Chang, Yi-Hao Yen, Cheng-Kun Wu, Ming-Tsung Lin, Tsung-Hui Hu. Comparison of tenofovir and entecavir in the development of acute kidney injury in cirrhotic chronic hepatitis B patients with refractory ascites.
European journal of gastroenterology & hepatology.
2021 02; 32(2):208-213. doi:
10.1097/meg.0000000000001711. [PMID: 32371826] - Lihua Huang, Li Zhou, Jianhe Gan, Wenlong Yang, Yaping Dai, Tingting Su, Yuanwang Qiu. IL-21 Is Associated With Virological Relapse of HBeAg Positive Chronic Hepatitis B After Discontinuance of Entecavir.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.
2021 02; 32(2):178-186. doi:
10.5152/tjg.2021.19703. [PMID: 33960942] - Te-Sheng Chang, Yao-Hsu Yang, Wei-Ming Chen, Chien-Heng Shen, Shui-Yi Tung, Chih-Wei Yen, Yung-Yu Hsieh, Chuan-Pin Lee, Meng-Ling Tsai, Chao-Hung Hung, Sheng-Nan Lu. Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B.
Scientific reports.
2021 01; 11(1):1365. doi:
10.1038/s41598-020-80523-7. [PMID: 33446835] - Hideo Takayama, Takuya Komura, Takashi Kagaya, Saiho Sugimoto, Noriaki Orita, Yoshiro Asahina, Masashi Nishikawa, Hajime Ohta, Shuichi Kaneko, Masashi Unoura. Clinical Features and Resistance to Entecavir Monotherapy of Patients with Hepatitis B.
Canadian journal of gastroenterology & hepatology.
2021; 2021(?):3259833. doi:
10.1155/2021/3259833. [PMID: 34422709] - Yaxian Ma, Li Yang, Yuhan Bao, Yang Yang, Liting Chen, Miao Zheng. Case Report: Post-CAR-T Infusion HBV Reactivation in Two Lymphoma Patients Despite Entecavir Preventive Therapy.
Frontiers in immunology.
2021; 12(?):751754. doi:
10.3389/fimmu.2021.751754. [PMID: 34691067] - Seong Hee Kang, Dong-Hyuk Cho, Jimi Choi, Soon Koo Baik, Jun Gyo Gwon, Moon Young Kim. Association between chronic hepatitis B infection and COVID-19 outcomes: A Korean nationwide cohort study.
PloS one.
2021; 16(10):e0258229. doi:
10.1371/journal.pone.0258229. [PMID: 34610052] - Tao Yang, Tian-Hui Zheng, Qiang Zhao, Wei Liu, Shu-Ping Li, Yan-Yan Tao, Chang-Hong Wang, Cheng-Hai Liu. Effects of Fuzheng Huayu recipe on entecavir pharmacokinetics in normal and dimethylnitrosamine-induced hepatic fibrosis rats.
Pharmaceutical biology.
2020 Dec; 58(1):1-7. doi:
10.1080/13880209.2019.1687527. [PMID: 31847670] - Minseok Albert Kim, Seung Up Kim, Dong Hyun Sinn, Jeong Won Jang, Young-Suk Lim, Sang Hoon Ahn, Jae-Jun Shim, Yeon Seok Seo, Yang Hyun Baek, Sang Gyune Kim, Young Seok Kim, Ji Hoon Kim, Won Hyeok Choe, Hyung Joon Yim, Hyun Woong Lee, Jung Hyun Kwon, Sung Won Lee, Jae Young Jang, Hwi Young Kim, Yewan Park, Gi-Ae Kim, Hyun Yang, Han Ah Lee, Myeongseok Koh, Young-Sun Lee, Minkoo Kim, Young Chang, Yoon Jun Kim, Jung-Hwan Yoon, Fabien Zoulim, Jeong-Hoon Lee. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.
Gut.
2020 12; 69(12):2214-2222. doi:
10.1136/gutjnl-2019-320015. [PMID: 32209606] - Shao-Ming Chiu, Yuan-Hung Kuo, Jing-Houng Wang, Chao-Hung Hung, Tsung-Hui Hu, Sheng-Nan Lu, Chien-Hung Chen. Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
2020 12; 18(13):2989-2997.e3. doi:
10.1016/j.cgh.2020.04.048. [PMID: 32353534] - Xiaoke Li, Daqiao Zhou, Xiaoling Chi, Qin Li, Li Wang, Bingjiu Lu, Dewen Mao, Qikai Wu, Xianbo Wang, Mingxiang Zhang, Jingdong Xue, Yong Li, Wei Lu, Jianchun Guo, Feng Jiang, Xinwei Zhang, Zhiguo Li, Xianzhao Yang, Hui Guo, Danan Gan, Liyun He, Lin Luo, Ludan Zhang, Hongbo Du, Yong'an Ye. Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial.
Hepatology international.
2020 Dec; 14(6):985-996. doi:
10.1007/s12072-020-10097-z. [PMID: 33128206] - Si-Si Yang, Cheng-Wei Cai, Xue-Qing Ma, Jia Xu, Cheng-Bo Yu. Efficacy and cost-effectiveness of antiviral regimens for entecavir-resistant hepatitis B: A systematic review and network meta-analysis.
Hepatobiliary & pancreatic diseases international : HBPD INT.
2020 Dec; 19(6):507-514. doi:
10.1016/j.hbpd.2020.09.007. [PMID: 33051132] - Lifen Wang, Bingying Xie, Quan Zheng, Lixia Xu, Zhiming Ye. Efficacy of entecavir in treating hepatitis B virus-associated membranous nephropathy.
Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.
2020 Nov; 112(11):843-849. doi:
10.17235/reed.2020.6762/2019. [PMID: 33054304] - Li Su, Ye Tu, De-Pei Kong, Da-Gui Chen, Chen-Xi Zhang, Wan-Nian Zhang, Chun-Lin Zhuang, Zhi-Bin Wang. Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2020 Nov; 131(?):110643. doi:
10.1016/j.biopha.2020.110643. [PMID: 32846329] - Xiaomei Wang, Zhongfeng Wang, Xiumei Chi, Ruihong Wu, Qinglong Jin, Hongqin Xu, Xiuzhu Gao, Lei Yu, Yuping Chen, Jia Shang, Longgen Liu, Shuqin Zhang, Yongfang Jiang, Mingxiang Zhang, Qiaoxia Tong, Lunli Zhang, Youwen Tan, Anlin Ma, Shuangsuo Dang, Bin Xu, Zhenjing Jin, Jia Li, Xiaobo Li, Fengmin Lu, Junqi Niu. Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
2020 Oct; 99(?):171-178. doi:
10.1016/j.ijid.2020.07.031. [PMID: 32721532] - Luisa Roade, Alessandro Loglio, Marta Borghi, Mar Riveiro-Barciela, Roberta Soffredini, Floriana Facchetti, Dhanai di Paolo, David Tabernero, Giovanna Lunghi, Rafael Esteban, Maria Buti, Pietro Lampertico. Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
2020 10; 52(10):1164-1169. doi:
10.1016/j.dld.2020.06.037. [PMID: 32703729] - Lung-Yi Mak, Kwan-Lung Ko, Wai-Pan To, Danny Ka-Ho Wong, Wai-Kay Seto, James Fung, Man-Fung Yuen. Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma.
Gut and liver.
2020 09; 14(5):665-668. doi:
10.5009/gnl19434. [PMID: 32457279] - Yue Ming, Guang Xin, Beihong Ji, Chengji Ji, Zeliang Wei, Boli Zhang, Junhua Zhang, Kui Yu, Xiaoyu Zhang, Shiyi Li, Youping Li, Zhihua Xing, Hai Niu, Wen Huang. Entecavir as a P2X7R antagonist ameliorates platelet activation and thrombus formation.
Journal of pharmacological sciences.
2020 Sep; 144(1):43-51. doi:
10.1016/j.jphs.2020.07.002. [PMID: 32653340] - Mi Young Jeon, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Sang Hoon Ahn, Seung Up Kim. Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma.
Journal of viral hepatitis.
2020 09; 27(9):932-940. doi:
10.1111/jvh.13313. [PMID: 32365240] - Xiao-Qi Yu, Ming-Jie Wang, De-Min Yu, Pei-Zhan Chen, Ming-Yu Zhu, Wei Huang, Yue Han, Qi-Ming Gong, Xin-Xin Zhang. Comparison of Serum Hepatitis B Virus RNA Levels and Quasispecies Evolution Patterns between Entecavir and Pegylated-Interferon Mono-treatment in Chronic Hepatitis B Patients.
Journal of clinical microbiology.
2020 08; 58(9):. doi:
10.1128/jcm.00075-20. [PMID: 32554476] - Xiaoke Li, Ludan Zhang, Mei Qiu, Yi Huang, Huanming Xiao, Bingjiu Lu, Yuyong Jiang, Fuli Long, Hui Lin, Jinyu He, Qikai Wu, Mingxiang Zhang, Li Wang, Xiaoning Zhu, Man Gong, Xuehua Sun, Jianguang Sun, Fengxia Sun, Wei Lu, Weihua Xu, Guang Chen, Zhiguo Li, Danan Gan, Xianzhao Yang, Hongbo Du, Yong'an Ye. Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multicener, double-blind, randomized controlled trial in China.
Trials.
2020 Aug; 21(1):708. doi:
10.1186/s13063-020-04417-9. [PMID: 32787905] - Rongjuan Chen, Yan Liu, Dan Luo, Lanlan Si, Bixia Huang, Jun Wang, Xiaodong Li, Fengjuan Cheng, Dongping Xu, Changzhu Duan. Hepatitis B virus mutation pattern rtA181S+T184I+M204I may contribute to multidrug resistance in clinical practice: Analysis of a large cohort of Chinese patients.
Antiviral research.
2020 08; 180(?):104852. doi:
10.1016/j.antiviral.2020.104852. [PMID: 32569703] - Steffen Jockusch, Chuanjuan Tao, Xiaoxu Li, Thomas K Anderson, Minchen Chien, Shiv Kumar, James J Russo, Robert N Kirchdoerfer, Jingyue Ju. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.
Antiviral research.
2020 08; 180(?):104857. doi:
10.1016/j.antiviral.2020.104857. [PMID: 32562705] - Juhan Lee, Jun Yong Park, Seok Jeong Yang, Jee Youn Lee, Deok Gie Kim, Dong Jin Joo, Myoung Soo Kim, Soon Il Kim, Jae Geun Lee. Renal safety of tenofovir disoproxil fumarate and entecavir with hepatitis B immunoglobulin in liver transplant patients.
Journal of viral hepatitis.
2020 08; 27(8):818-825. doi:
10.1111/jvh.13291. [PMID: 32302037] - Maoyuan Cheng, Xianrong Feng, Long Wang, Yu Yang, Li Ma, Baojia Wang. Nucleoside analogs assisted with Chinese compound prescription in treating hepatic fibrosis of chronic hepatitis B patients: A protocol of systematic review and meta-analysis.
Medicine.
2020 Jul; 99(27):e21032. doi:
10.1097/md.0000000000021032. [PMID: 32629728] - Hyun Young Woo, Jun Yong Park, Si Hyun Bae, Chang Wook Kim, Jae Young Jang, Won Young Tak, Dong Joon Kim, In Hee Kim, Jeong Heo, Sang Hoon Ahn. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.
Clinical and molecular hepatology.
2020 07; 26(3):352-363. doi:
10.3350/cmh.2019.0044n. [PMID: 32460460] - Xingxing Li, Shuo Wu, Yu Du, Lu Yang, Yuhuan Li, Bin Hong. Entecavir therapy reverses gut microbiota dysbiosis induced by hepatitis B virus infection in a mouse model.
International journal of antimicrobial agents.
2020 Jul; 56(1):106000. doi:
10.1016/j.ijantimicag.2020.106000. [PMID: 32360229] - Eiichi Ogawa, Hideyuki Nomura, Makoto Nakamuta, Norihiro Furusyo, Toshimasa Koyanagi, Kazufumi Dohmen, Aritsune Ooho, Takeaki Satoh, Akira Kawano, Eiji Kajiwara, Kazuhiro Takahashi, Koichi Azuma, Masaki Kato, Shinji Shimoda, Jun Hayashi. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Liver international : official journal of the International Association for the Study of the Liver.
2020 07; 40(7):1578-1589. doi:
10.1111/liv.14482. [PMID: 32304611] - Qing-Juan Wu, Wen-Liang Lv, Juan-Mei Li, Ting-Ting Zhang, Wen-Hui Zhou, Qiang Zhang, Jiu-Chong Wang, Qing-Nan Wang, Ruo-Xuan Zhang, Xin Zhao, Si-Tong Chen, Shuang Liu, Gao-Hui Li, Zheng-Min Cao, Lei Xu, Jing Chen. Efficacy and safety of YinQiSanHuang-antiviral decoction in chronic hepatitis B: study protocol for a randomized, placebo-controlled, double-blinded trial.
Trials.
2020 Jun; 21(1):482. doi:
10.1186/s13063-020-04395-y. [PMID: 32503608] - Rania A Tawfeek, Ehsan A Hassan, Mohammed S Badary, Sherif I Kamel, Mohammed A El-Mokhtar, Entsar H Ahmed. IP-10 Levels in Patients Infected with HBV Predicts The Response to Treatment with Entecavir.
The Egyptian journal of immunology.
2020 Jun; 27(2):47-57. doi:
. [PMID: 33548977] - Chih-Jen Chen, Hsien-Chung Yu, Chen-Wang Chang, Ming-Jong Bair, Ching-Chung Lin, Yang-Sheng Lin, Zong-Sian Cai, Ming-Jen Chen. Efficacy of telbivudine and entecavir against virus reactivation in HBeAg-patients undergoing chemotherapy.
Medicine.
2020 May; 99(22):e20330. doi:
10.1097/md.0000000000020330. [PMID: 32481407] - Shuanghui Lu, Xi Yang, Ting Jiang, Hui Zhou, Wei Wang, Nengming Lin, Su Zeng, Zhiyuan Ma, Huidi Jiang. Pregnancy Impacts Entecavir Pharmacokinetics but Does Not Alter Its Renal Excretion.
Journal of pharmaceutical sciences.
2020 05; 109(5):1811-1818. doi:
10.1016/j.xphs.2020.01.027. [PMID: 32027922] - Kazumoto Murata, Senko Tsukuda, Futoshi Suizu, Akihiro Kimura, Masaya Sugiyama, Koichi Watashi, Masayuki Noguchi, Masashi Mizokami. Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus Infection.
Hepatology (Baltimore, Md.).
2020 05; 71(5):1533-1545. doi:
10.1002/hep.30956. [PMID: 31529730] - Takanori Mei, Hiroshi Noguchi, Yu Hisadome, Keizo Kaku, Takehiro Nishiki, Yasuhiro Okabe, Masafumi Nakamura. Hepatitis B virus reactivation in kidney transplant patients with resolved hepatitis B virus infection: Risk factors and the safety and efficacy of preemptive therapy.
Transplant infectious disease : an official journal of the Transplantation Society.
2020 Apr; 22(2):e13234. doi:
10.1111/tid.13234. [PMID: 31856328] - Yong-Hong Wang, Juan Liao, Dong-Mei Zhang, Dong-Bo Wu, Ya-Chao Tao, Meng-Lan Wang, En-Qiang Chen, Hong Tang. Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir.
Journal of medical virology.
2020 03; 92(3):302-308. doi:
10.1002/jmv.25608. [PMID: 31609007] - Jonggi Choi, Gi-Ae Kim, Seungbong Han, Young-Suk Lim. Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B.
The American journal of gastroenterology.
2020 03; 115(3):406-414. doi:
10.14309/ajg.0000000000000490. [PMID: 31895708] - Yoshihito Uchida, Masamitsu Nakao, Shohei Tsuji, Hayato Uemura, Jun-Ichi Kouyama, Kayoko Naiki, Daisuke Motoya, Kayoko Sugawara, Nobuaki Nakayama, Yukinori Imai, Tomoaki Tomiya, Satoshi Mochida. Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
Journal of medical virology.
2020 03; 92(3):329-338. doi:
10.1002/jmv.25644. [PMID: 31777965] - Baolian Liu, Bingbing Shen, Mei Mei, Lina Li, Xiaohong Wang, Hongwen Zhao. Potential Effects of Telbivudine Versus Entecavir on Renal Function in Patients With Chronic Hepatitis B Virus Receiving Glucocorticoids Therapy.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
2020 Feb; 24(1):56-63. doi:
10.1111/1744-9987.12839. [PMID: 31090170] - Zhidan Zheng, Wei Liao, Lili Liu, Shaohang Cai, Haipeng Zhu, Sichun Yin. Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2020 Feb; 122(?):109698. doi:
10.1016/j.biopha.2019.109698. [PMID: 31918272] - Wenying Shu, Lei Ma, Xiaoye Hu, Meimei Zhang, Wensheng Chen, Wen Ma, Jianing Huang, Jia Li. Drug-drug interaction between crizotinib and entecavir via renal secretory transporter OCT2.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2020 Jan; 142(?):105153. doi:
10.1016/j.ejps.2019.105153. [PMID: 31740393] - Kai Zhang, Su Lin, Mingfang Wang, Jiaofeng Huang, Yueyong Zhu. The Risk of Acute Kidney Injury in Hepatitis B Virus-Related Acute on Chronic Liver Failure with Tenofovir Treatment.
BioMed research international.
2020; 2020(?):5728359. doi:
10.1155/2020/5728359. [PMID: 32596332] - Amit Goel, Sumit Rungta, Prashant Verma, Abhai Verma, Ajay Narayan Verma, Praveer Rai, Rakesh Aggarwal. Viral suppression is comparable with 0.5 mg and 1.0 mg daily doses of entecavir in treatment-naive HBV-related decompensated cirrhosis.
Antiviral therapy.
2020; 25(5):267-273. doi:
10.3851/imp3375. [PMID: 33404519] - Mohamed Hamdi, Hend Mohamed Abdel-Bar, Enas Elmowafy, Khuloud T Al-Jamal, Gehanne A S Awad. An integrated vitamin E-coated polymer hybrid nanoplatform: A lucrative option for an enhanced in vitro macrophage retention for an anti-hepatitis B therapeutic prospect.
PloS one.
2020; 15(1):e0227231. doi:
10.1371/journal.pone.0227231. [PMID: 31923260] - Yunxia Wang, Jiayuan Zhang, Yuxia Jin, Xiao Xiao, Qi Zhang. Kushenin combined with entecavir for chronic hepatitis B: A protocol for a systematic review and meta-analysis.
Medicine.
2020 Jan; 99(5):e18898. doi:
10.1097/md.0000000000018898. [PMID: 32000393] - Marie-Laure Cambier, Ana Canestri, Catherine Lependeven, Julie Peltier, Laurent Mesnard, Karine Dahan. Hepatitis B virus reactivation during belatacept treatment after kidney transplantation.
Transplant infectious disease : an official journal of the Transplantation Society.
2019 Dec; 21(6):e13170. doi:
10.1111/tid.13170. [PMID: 31505095] - Tianyao Zhang, Yu Yang, Baojia Wang, Xiuli Zheng, Long Wang, Xianrong Feng, Guiyu Li, Jinyu Shi, Ning Cao. Meta-analysis of influences of Biejiajian Pill combined with entecavir on serum liver fibrosis markers of compensatory period of hepatitis b cirrhosis: Protocol of systematic review and meta-analysis.
Medicine.
2019 Dec; 98(51):e18458. doi:
10.1097/md.0000000000018458. [PMID: 31861022] - Jia Wei, Xiaojian Zhu, Xia Mao, Liang Huang, Fankai Meng, Jianfeng Zhou. Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma.
Journal for immunotherapy of cancer.
2019 11; 7(1):315. doi:
10.1186/s40425-019-0790-y. [PMID: 31753002] - Teruhiro Fujii, Kentaro Kawasoe, Akihito Ohta, Kosaku Nitta. A case of entecavir-induced Fanconi syndrome.
CEN case reports.
2019 11; 8(4):256-260. doi:
10.1007/s13730-019-00404-5. [PMID: 31154657]